The American Diabetes Association, backed by several other medical groups, sponsored an opinion paper concluding some anti-psychotic medicines carry more diabetes risk than others and the FDA's decision to apply the same warning to all such medicines should be changed. Eli Lilly, maker of Zyprexa, a schizophrenia drug, said it does not agree with the conclusions of the paper, which also warned the inconsistency in warnings could confuse doctors and patients.

Full Story:

Related Summaries